Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Diabetes Mellitus

Diabetes Mellitus, Type 2

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Hypoglycemic Agents

All Drugs and Chemicals

Anti-Arrhythmia Agents

Metformin

Gliclazide

Glimepiride

Glyburide

Rosiglitazone

Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.

allocation of treatment with metformin or rosiglitazone

GSK Clinical Trials

Observational analyses of data from population registeries have suggested that metformin may be associated with a decreased prevalence of malignancy. The ADOPT and RECORD studies both contain groups of subjects randomly allocated to metformin and rosiglitazone. This meta-analysis combines malignancy serious adverse events from ADOPT and RECORD in order to compare their incidence on metformin with that on rosiglitazone.

The objective of this meta-analysis is to compare the incidence of malignancy (excluding non-melanomatous skin cancers) reported as serious adverse events in the ADOPT and RECORD studies between subjects randomly allocated to treatment with metformin with those allocated to rosiglitazone.

Malignancy Meta Analysis for BRL49653

A Meta Analysis of Malignancy Serious Adverse Events in the ADOPT, 49653/048, and RECORD, 49653/231, Studies, Comparing Metformin With Rosiglitazone.

GlaxoSmithKline

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Malignancy Meta Analysis for BRL49653	NCT01195259	Diabetes Mellit...	allocation of t...	-	GlaxoSmithKline
Malignancy Meta Analysis for BRL49653	NCT01195259	Diabetes Mellit...	allocation of t...	-	GlaxoSmithKline
Malignancy Meta Analysis for BRL49653	NCT01195259	Diabetes Mellit...	allocation of t...	-	GlaxoSmithKline

Spots Global Cancer Trial Database for allocation of treatment with metformin or rosiglitazone